Pelthos Therapeutics Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Pelthos Therapeutics Inc. (PTHS) reported Revenue from Contract with Customer, Excluding Assessed Tax of $15.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- Pelthos Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $15.60M.
- Pelthos Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $10.91M.
- Pelthos Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $16.50M.
- Pelthos Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $294.00K.
- Pelthos Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $16.80M.
- Pelthos Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.60M 10-Q · filed 2026-08-13 | $26.51M 10-Q · filed 2026-08-13 | $43.01M derived: sum of 3 quarters · filed 2026-08-13 | $43.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $10.91M 10-Q/A · filed 2026-08-13 | $27.41M derived: sum of 2 quarters · filed 2026-08-13 | $27.70M derived: sum of 3 quarters · filed 2026-08-13 | $27.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $16.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $16.80M derived: sum of 2 quarters · filed 2026-03-19 | $16.80M derived: sum of 3 quarters · filed 2026-08-13 | $16.80M 10-K · filed 2026-03-19 |
| 2025-09-30 | $294.00K 10-Q · filed 2025-11-13 | $294.00K derived: sum of 2 quarters · filed 2026-08-13 | $294.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $0.00 10-Q/A · filed 2026-08-13 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |